Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03306641 · ClinicalTrials.gov registry record · NA

A One-Week Crossover Dispensing Evaluation of New Daily Wear Soft Contact Lenses

A NA study of Myopia, sponsored by CooperVision.

Completed
Registry status
NA
Development phase
45
Enrollment target
1
Study location

NCT03306641 is a NA study of Myopia that has completed, run by CooperVision. The registered enrollment target is 45 participants, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03306641, a NA study of Myopia, has completed, sponsored by CooperVision.

COMPLETED
Registry status
NA
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to validate the clinical performance of a new contact lens design when worn over a period 1 week compared to nelfilcon A (control).

Conditions Studied

Myopia

Interventions

  • DEVICE Test Contact Lens
  • DEVICE Nelfilcon A

Study Locations (1)

Indiana

  • Clinical Optics Research Lab (CORL) Indiana University School of Optometry, Indiana University - Bloomington

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2017-07-28
Est. Completion 2017-08-31
Phase NA

Sponsor

CooperVision

64 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03306641

The ClinicalTrials.gov registry entry for NCT03306641 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (83% lower). The listed sponsor is CooperVision, which has 64 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Test Contact Lens is the first listed.

NCT03306641 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT03306641 about?

NCT03306641 is a clinical study titled "A One-Week Crossover Dispensing Evaluation of New Daily Wear Soft Contact Lenses". The purpose of this study is to validate the clinical performance of a new contact lens design when worn over a period 1 week compared to nelfilcon A (control).

What is the current status of trial NCT03306641?

This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2017-07-28. Estimated completion is 2017-08-31.

What conditions does trial NCT03306641 study?

This clinical trial studies the following conditions: Myopia.

What interventions are being tested in trial NCT03306641?

The interventions under investigation include: Test Contact Lens (DEVICE), Nelfilcon A (DEVICE).

Who is sponsoring clinical trial NCT03306641?

This trial is sponsored by CooperVision, which has 64 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03306641 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myopia

All registered trials for this condition

Indiana

All trials with a study site in Indiana

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.